# Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

> **NCT03875144** · PHASE2 · SUSPENDED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 66 (estimated)

## Conditions studied

- Peritoneal Mesothelioma
- Peritoneal Carcinomatosis

## Interventions

- **PROCEDURE:** PIPAC
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03875144
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-09-10
- **Primary completion:** 2024-12-16
- **Final completion:** 2027-06
- **Target enrollment:** 66 (ESTIMATED)
- **Why stopped:** This decision was taken following the occurrence of three cases of serious and unexpected suspected adverse reactions (SUSARs), specifically febrile neutropenia, in participants assigned to the experimental arm combining PIPAC with systemic chemothe
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875144, "Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03875144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*